临床试验
观点
医学
加药
家庭医学
替代医学
立场文件
重症监护医学
医学物理学
儿科
病理
内科学
艺术
视觉艺术
作者
Dan Turner,Anne M. Griffiths,David C. Wilson,Diane R. Mould,Robert N. Baldassano,Richard K. Russell,Marla C. Dubinsky,Melvin B. Heyman,Lissy de Ridder,Jeffrey S. Hyams,Javier Martín de Carpi,Laurie S. Conklin,William A. Faubion,Sibylle Koletzko,Athos Bousvaros,Frank M. Ruemmele
出处
期刊:Gut
[BMJ]
日期:2019-04-12
卷期号:69 (1): 32-41
被引量:53
标识
DOI:10.1136/gutjnl-2018-317987
摘要
Introduction The optimal trial design for assessing novel therapies in paediatric IBD (PIBD) is a subject of intense ongoing global discussions and debate among the different stakeholders. However, there is a consensus that the current situation in which most medications used in children with IBD are prescribed as off-label without sufficient paediatric data is unacceptable. Shortening the time lag between adult and paediatric approval of drugs is of the upmost importance. In this position paper we aimed to provide guidance from the global clinical research network (Pediatric Inflammatory Bowel Disease Network, PIBDnet) for designing clinical trials in PIBD in order to facilitate drug approval for children. Methods A writing group has been established by PIBDnet and topics were assigned to different members. After an iterative process of revisions among the writing group and one face-to-face meeting, all statements have reached consensus of >80% as defined a priori. Next, all core members of PIBDnet voted on the statements, reaching consensus of >80% on all statements. Comments from the members were incorporated in the text. Results The commentary includes 18 statements for guiding data extrapolation from adults, eligibility criteria to PIBD trials, use of placebo, dosing, endpoints and recommendations for feasible trials. Controversial issues have been highlighted in the text. Conclusion The viewpoints expressed in this paper could assist planning clinical trials in PIBD which are both of high quality and ethical, while remaining pragmatic.
科研通智能强力驱动
Strongly Powered by AbleSci AI